Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis.

Foley J, Carrillo-Infante C, Smith J, Evans K, Ho PR, Lee L, Kasliwal R, Stangel M, Vermersch P, Hutchinson M, Marinelli F, Smirnakis K; TYGRIS investigators.

Mult Scler Relat Disord. 2019 Nov 21;39:101863. doi: 10.1016/j.msard.2019.101863. [Epub ahead of print]

PMID:
31901758
2.

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.

Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, Goldberg JD, Li X, Riddle E, Smirnakis K, Kasliwal R, Ren Z, Hotermans C, Ho PR, Campbell N.

Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12.

PMID:
31515290
3.

The development of sarcoidosis in patients receiving daclizumab: A case series from multiple clinical trials.

Judson MA, Elicker BM, Colby TV, Kwon S, de Windt E, Chalkias S, Prada C, Smirnakis K, Singhal P.

Respir Med. 2019 Mar;149:23-27. doi: 10.1016/j.rmed.2019.01.015. Epub 2019 Feb 1.

PMID:
30885425
4.

Risk of pure red cell aplasia in patients with hepatitis C receiving antiviral therapy and an erythropoiesis-stimulating agent.

Rossert J, Yue S, Smirnakis K, Mytych DT, Johnson L, Kouchakji E, Casadevall N.

Clin Gastroenterol Hepatol. 2014 Feb;12(2):341-5. doi: 10.1016/j.cgh.2013.09.065. Epub 2013 Oct 9.

PMID:
24120841
5.

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.

Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA.

J Am Coll Cardiol. 2012 Nov 6;60(19):1888-98. doi: 10.1016/j.jacc.2012.08.986. Epub 2012 Oct 17.

6.

The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study.

Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, Goodman WG, Rothman KJ.

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):914-21. doi: 10.1002/pds.2183. Epub 2011 Jul 7.

PMID:
21735509
7.

Consistent control of mineral and bone disorder in incident hemodialysis patients.

Danese MD, Belozeroff V, Smirnakis K, Rothman KJ.

Clin J Am Soc Nephrol. 2008 Sep;3(5):1423-9. doi: 10.2215/CJN.01060308. Epub 2008 Jul 2.

8.

Predicting gestational diabetes: choosing the optimal early serum marker.

Smirnakis KV, Plati A, Wolf M, Thadhani R, Ecker JL.

Am J Obstet Gynecol. 2007 Apr;196(4):410.e1-6; discussion 410.e6-7.

PMID:
17403439
9.

Postpartum diabetes screening in women with a history of gestational diabetes.

Smirnakis KV, Chasan-Taber L, Wolf M, Markenson G, Ecker JL, Thadhani R.

Obstet Gynecol. 2005 Dec;106(6):1297-303.

PMID:
16319255
10.

Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies.

Wolf M, Shah A, Lam C, Martinez A, Smirnakis KV, Epstein FH, Taylor RN, Ecker JL, Karumanchi SA, Thadhani R.

Am J Obstet Gynecol. 2005 Jul;193(1):16-22.

PMID:
16021053
11.

Early pregnancy insulin resistance and subsequent gestational diabetes mellitus.

Smirnakis KV, Martinez A, Blatman KH, Wolf M, Ecker JL, Thadhani R.

Diabetes Care. 2005 May;28(5):1207-8. No abstract available.

PMID:
15855591
12.

Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia.

Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, Levine RJ, Karumanchi SA.

Hypertension. 2004 May;43(5):988-92. Epub 2004 Mar 15.

PMID:
15023932
13.

Role of hydration in the binding of lac repressor to DNA.

Fried MG, Stickle DF, Smirnakis KV, Adams C, MacDonald D, Lu P.

J Biol Chem. 2002 Dec 27;277(52):50676-82. Epub 2002 Oct 11.

Supplemental Content

Loading ...
Support Center